Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.83 |
|---|---|
| High | 0.83 |
| Low | 0.75 |
| Bid | 0.78 |
| Offer | 0.79 |
| Previous close | 0.80 |
| Average volume | 91.50k |
|---|---|
| Shares outstanding | 83.41m |
| Free float | 65.90m |
| P/E (TTM) | -- |
| Market cap | 66.73m CAD |
| EPS (TTM) | -0.1696 CAD |
Data delayed at least 15 minutes, as of Feb 10 2026 20:59 GMT.
More ▼
- Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
- Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
- Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data
- Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
- Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma
- Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
- Medicenna Therapeutics Announces Participation in Upcoming Conferences
- Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
- Medicenna Announces Results of Annual Meeting of Shareholders
- Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
More ▼
